Kate Khair
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kate Khair has a total of 235 co-authors. Here are the top co-authors by number of shared publications:
- Mike Holland
Haemnet, London, UK
20 shared publications - Simon Fletcher
University of Oxford
13 shared publications - Paul McLaughlin
Katharine Dormandy Haemophilia and Thrombosis Centre Royal Free Hospital London UK
10 shared publications - Kathryn Jenner
Haemnet Ltd , London , UK
9 shared publications - Debra Pollard
Katharine Dormandy Haemophilia & Thrombosis Centre , Royal Free Hospital , London , UK
8 shared publications - Sylvia von Mackensen
Department of Medical Psychology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
8 shared publications
Latest Publications
- Open Access
- 28 October 2026
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
Burden of von Willebrand disease in children and adolescents: post hoc analysis of a European cross-sectional study
- 28 October 2026
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
Open AccessBurden of von Willebrand disease in children and adolescents: post hoc analysis of a European cross-sectional study
- Open Access
- 26 October 2026
- Published by Haemnet Ltd in Bleeding Disorders Care & Practice
- p. 57
The Paradox of 'Non-Severe' Haemophilia: Qualitative Analysis of Treatment Disparities and Quality of Life Impacts from the Learning to Live Study
Background: Non-factor replacement therapies and gene therapy for severe haemophilia convert the bleeding phenotype to mild or moderate. People with haemophilia (PwH) who transition to a milder phenotype as a result of their treatment may require a greater degree of ongoing care and support than those with genetically mild or moderate haemophilia, due to previous bleeding episodes. Assessing the subjective experiences of PwH with genetically mild or moderate haemophilia compared to those converted to a milder phenotype enables a comparison of expectations across the spectrum of the disease. Understanding the lived experience of genetically mild and moderate haemophilia can therefore inform the anticipated care needs of the growing group whose treatment converts a severe phenotype to a non-severe one. Methods: Qualitative interviews were undertaken as part of a mixed-methods study examining the lived experience of non-severe haemophilia. Forty-four men with haemophilia (15 mild, 10 moderate, 11 severe, 8 post-gene therapy) aged 16-76 years were interviewed between January and August 2023. Interviews were recorded, transcribed, and thematically analysed using NVivo software, with cross-validation by two researchers. Analysis followed a grounded theory-informed approach. Results: Five main themes emerged within the overarching theme of Ability vs. Disability: 1) Acceptance vs. Rejection, 2) Benefits vs. Burdens, 3) Control vs. Uncertainty, 4) Freedom vs. Constraint, 5) The Future vs. the Past. Participants with genetically non-severe haemophilia reported significant treatment disparities compared to those with severe haemophilia, including delayed diagnosis, inability to self-treat, and limited access to prophylaxis. Despite higher factor levels, individuals with non-severe haemophilia and those who had transitioned to a non-severe phenotype experienced similar issues with regard to bleeding episodes. Paradoxically, while participants reported their condition did not significantly impact daily life, they described constant background concerns about injuries and activity limitations. Conclusions: PwH of all severities experience similar quality of life impacts, particularly during bleeding episodes. Treatment disparities must be addressed to improve outcomes for those with non-severe haemophilia, including individuals on phenotype-altering treatments. Recommendations include facilitating self-infusion and home treatment for all severity levels, ensuring rapid access to bleed assessment and follow-up regardless of primary diagnosis, and addressing the mixed messaging from healthcare teams regarding activity restrictions and treatment protocols.
- 26 October 2026
- Published by Haemnet Ltd in Bleeding Disorders Care & Practice
- p. 57
Open AccessThe Paradox of 'Non-Severe' Haemophilia: Qualitative Analysis of Treatment Disparities and Quality of Life Impacts from the Learning to Live Study
Background: Non-factor replacement therapies and gene therapy for severe haemophilia convert the bleeding phenotype to mild or moderate. People with haemophilia (PwH) who transition to a milder phenotype as a result of their treatment may require a greater degree of ongoing care and support than those with genetically mild or moderate haemophilia, due to previous bleeding episodes. Assessing the subjective experiences of PwH with genetically mild or moderate haemophilia compared to those converted to a milder phenotype enables a comparison of expectations across the spectrum of the disease. Understanding the lived experience of genetically mild and moderate haemophilia can therefore inform the anticipated care needs of the growing group whose treatment converts a severe phenotype to a non-severe one. Methods: Qualitative interviews were undertaken as part of a mixed-methods study examining the lived experience of non-severe haemophilia. Forty-four men with haemophilia (15 mild, 10 moderate, 11 severe, 8 post-gene therapy) aged 16-76 years were interviewed between January and August 2023. Interviews were recorded, transcribed, and thematically analysed using NVivo software, with cross-validation by two researchers. Analysis followed a grounded theory-informed approach. Results: Five main themes emerged within the overarching theme of Ability vs. Disability: 1) Acceptance vs. Rejection, 2) Benefits vs. Burdens, 3) Control vs. Uncertainty, 4) Freedom vs. Constraint, 5) The Future vs. the Past. Participants with genetically non-severe haemophilia reported significant treatment disparities compared to those with severe haemophilia, including delayed diagnosis, inability to self-treat, and limited access to prophylaxis. Despite higher factor levels, individuals with non-severe haemophilia and those who had transitioned to a non-severe phenotype experienced similar issues with regard to bleeding episodes. Paradoxically, while participants reported their condition did not significantly impact daily life, they described constant background concerns about injuries and activity limitations. Conclusions: PwH of all severities experience similar quality of life impacts, particularly during bleeding episodes. Treatment disparities must be addressed to improve outcomes for those with non-severe haemophilia, including individuals on phenotype-altering treatments. Recommendations include facilitating self-infusion and home treatment for all severity levels, ensuring rapid access to bleed assessment and follow-up regardless of primary diagnosis, and addressing the mixed messaging from healthcare teams regarding activity restrictions and treatment protocols.
- Open Access
- 1 July 2026
- Published by Haemnet Ltd in Bleeding Disorders Care & Practice
- Vol. 13 (1)
Editorial: A new era for our journal
Former Editor-in-Chief Dr Kate Khair and current Editor-in-Chief Dr Maria E. Santaella discuss the origins of The Journal of Haemophilia Practice and its purpose, and the reasons for changing its title to Bleeding Disorders: Care & Practice. They also look to the journal's future.
- 1 July 2026
- Published by Haemnet Ltd in Bleeding Disorders Care & Practice
- Vol. 13 (1)
Open AccessEditorial: A new era for our journal
Former Editor-in-Chief Dr Kate Khair and current Editor-in-Chief Dr Maria E. Santaella discuss the origins of The Journal of Haemophilia Practice and its purpose, and the reasons for changing its title to Bleeding Disorders: Care & Practice. They also look to the journal's future.
- Open Access
- 27 January 2025
- Published by Wiley in Haemophilia
- Vol. 31 (2) , 207-213
Operationalising a Haemophilia Gene Editing Lexicon for Practical Use
Introduction: Gene editing therapies offer the possibility of substantial improvement in treatment and quality of life for people with haemophilia (PWH) in a landscape of dynamic therapeutic advancement. Developing a common and understandable language to discuss gene editing will be essential to ensure these treatments can be deployed in a safe and effective manner with fully informed and shared decision‐making between healthcare professionals (HCPs) and PWH. A lexicon explaining and clarifying key concepts is one potential tool to address these aims. Here we evaluate how a gene editing lexicon could be deployed to maximise impact and improve patient outcomes. Aim: To operationalise the gene editing lexicon for successful adoption by the haemophilia community. Methods: Through an innovative, iterative process, representatives from the haemophilia community, including multidisciplinary HCPs, PWH, and caregivers, with support from language strategy experts, developed a gene editing lexicon and evaluated operational aspects for real‐world adoption of this resource. Results: A gene editing lexicon was developed, including infographics illustrating key concepts. Infographics were adapted from the lexicon to further clarify and communicate these concepts. Infographics were found to be a potentially vital tool for enhancing the practical use of the lexicon to promote shared decision‐making and attain informed consent for gene editing therapies. Conclusion: A gene editing lexicon shows promise for improving the understanding of gene editing for all stakeholders in the haemophilia community. Ensuring the lexicon remains up to date with current therapies and appropriate strategies for adoption such as infographics will enable this resource to have maximum impact.
- 27 January 2025
- Published by Wiley in Haemophilia
- Vol. 31 (2) , 207-213
Open AccessOperationalising a Haemophilia Gene Editing Lexicon for Practical Use
Introduction: Gene editing therapies offer the possibility of substantial improvement in treatment and quality of life for people with haemophilia (PWH) in a landscape of dynamic therapeutic advancement. Developing a common and understandable language to discuss gene editing will be essential to ensure these treatments can be deployed in a safe and effective manner with fully informed and shared decision‐making between healthcare professionals (HCPs) and PWH. A lexicon explaining and clarifying key concepts is one potential tool to address these aims. Here we evaluate how a gene editing lexicon could be deployed to maximise impact and improve patient outcomes. Aim: To operationalise the gene editing lexicon for successful adoption by the haemophilia community. Methods: Through an innovative, iterative process, representatives from the haemophilia community, including multidisciplinary HCPs, PWH, and caregivers, with support from language strategy experts, developed a gene editing lexicon and evaluated operational aspects for real‐world adoption of this resource. Results: A gene editing lexicon was developed, including infographics illustrating key concepts. Infographics were adapted from the lexicon to further clarify and communicate these concepts. Infographics were found to be a potentially vital tool for enhancing the practical use of the lexicon to promote shared decision‐making and attain informed consent for gene editing therapies. Conclusion: A gene editing lexicon shows promise for improving the understanding of gene editing for all stakeholders in the haemophilia community. Ensuring the lexicon remains up to date with current therapies and appropriate strategies for adoption such as infographics will enable this resource to have maximum impact.
- Open Access
- 1 January 2025
- Published by Haemnet Ltd in The Journal of Haemophilia Practice
- Vol. 12 (1) , 141-149
CATCH 2024 meeting summary: Collaborate & Address Treatment Challenges in Haemophilia
Greater treatment choice and the associated flexibility in regimens has necessitated new conversations with people with haemophilia about their personal goals. Innovations in haemophilia treatment drive the need for innovation in care service delivery. Supported by Sobi™, CATCH (Collaborate & Address Treatment Challenges in Haemophilia) is an annual, non-promotional, medical education meeting that brings together members of the haemophilia multidisciplinary team from across the UK and Ireland to discuss all aspects of haemophilia care and management. This report summarises the key issues that were explored and discussed during the CATCH 2024 meeting, including understanding the personal motivations of people with haemophilia and how these influence treatment choices and support; facilitating behaviour change to improve outcomes; reviewing the practicalities and possibilities for eliminating bleeds and new arthropathy in people with haemophilia; and developing new models of care to elevate haemophilia services.
- 1 January 2025
- Published by Haemnet Ltd in The Journal of Haemophilia Practice
- Vol. 12 (1) , 141-149
Open AccessCATCH 2024 meeting summary: Collaborate & Address Treatment Challenges in Haemophilia
Greater treatment choice and the associated flexibility in regimens has necessitated new conversations with people with haemophilia about their personal goals. Innovations in haemophilia treatment drive the need for innovation in care service delivery. Supported by Sobi™, CATCH (Collaborate & Address Treatment Challenges in Haemophilia) is an annual, non-promotional, medical education meeting that brings together members of the haemophilia multidisciplinary team from across the UK and Ireland to discuss all aspects of haemophilia care and management. This report summarises the key issues that were explored and discussed during the CATCH 2024 meeting, including understanding the personal motivations of people with haemophilia and how these influence treatment choices and support; facilitating behaviour change to improve outcomes; reviewing the practicalities and possibilities for eliminating bleeds and new arthropathy in people with haemophilia; and developing new models of care to elevate haemophilia services.
- Open Access
- 1 January 2025
- Published by Haemnet Ltd in The Journal of Haemophilia Practice
- Vol. 12 (1) , 1-14
“I’d go on a hike with my kids… that would make me feel so happy.” Recognising what people with haemophilia B identify as meaningful when considering personal goals and the potential for gene therapy
Introduction: Historically people with haemophilia B (PwHB) have experienced adverse clinical outcomes including joint bleeds, pain and arthropathy. The current management of severe and moderate haemophilia B in the UK is largely through the use of factor replacement therapy often given as prophylaxis. Despite this, research reveals reduced quality of life (QoL) and psychological burden in PwHB of all severities, highlighting unmet need. Contemporary therapeutic developments including extended half-life factor IX products, novel non-factor agents, and gene therapy offer opportunities to address treatment-related issues and improve QoL. We investigated what PwHB identify as meaningful when considering their personal goals and the potential for gene therapy. Methods: UK men (aged >16 years) with severe or moderate haemophilia B were invited to take part in a face-to-face workshop or one-to-one online audio recorded interview. The recordings were transcribed verbatim, the transcripts were reviewed and coded using a process of inductive thematic analysis. We then used an iterative process to explore, review, reflect, and refine emergent codes and final themes. Ethical approval was not required based on the UK Health Research Authority decision tool. Results: Nine men, all with severe haemophilia B, aged 21 to 64 (median 34 years) participated. All were diagnosed as children; four had a previous family history and all described themselves as ‘well treated’ with self-managed home therapy and prophylaxis. None had received gene therapy. Parallels were observed in their goals. Thematic analysis classified them as achievable, unachievable and future goals. Achievable goals: Achieved despite living with haemophilia B, included education and employment, strong personal relationships, having a family, travelling, having a good social life and being able to participate in sports. Unachievable goals: Things that participants felt unable to achieve either now or in the future. These included changing attitudes of others, a recognition of lost opportunities including more physical, sporting and employment activities. Future goals: Those which might be achieved as treatments evolve. This included being more physically active, improved QoL for affected individuals and their families, greater ability to travel, and optimism for future treatments and their potential impact for future generations. The goals of PwHB often focused on personally meaningful everyday activities. Seemingly modest changes in individual circumstances could impact on QoL and wellbeing. QoL improvements were defined as equitable access to education and employment, increased confidence in undertaking physical activities, and greater ability to travel. Treatment innovations were identified as enhancing individualised patient preferences and reduced fear of bleeding along with its sequelae of pain and limited mobility. Conclusion: With improved access to novel therapeutic options, including gene therapy, PwHB are potentially able to experience equity to people without haemophilia in day-to-day life and activities. This will enable them to reimagine individual goals, their sense of what is ‘achievable’ and live their lives in personally meaningful ways.
- 1 January 2025
- Published by Haemnet Ltd in The Journal of Haemophilia Practice
- Vol. 12 (1) , 1-14
Open Access“I’d go on a hike with my kids… that would make me feel so happy.” Recognising what people with haemophilia B identify as meaningful when considering personal goals and the potential for gene therapy
Introduction: Historically people with haemophilia B (PwHB) have experienced adverse clinical outcomes including joint bleeds, pain and arthropathy. The current management of severe and moderate haemophilia B in the UK is largely through the use of factor replacement therapy often given as prophylaxis. Despite this, research reveals reduced quality of life (QoL) and psychological burden in PwHB of all severities, highlighting unmet need. Contemporary therapeutic developments including extended half-life factor IX products, novel non-factor agents, and gene therapy offer opportunities to address treatment-related issues and improve QoL. We investigated what PwHB identify as meaningful when considering their personal goals and the potential for gene therapy. Methods: UK men (aged >16 years) with severe or moderate haemophilia B were invited to take part in a face-to-face workshop or one-to-one online audio recorded interview. The recordings were transcribed verbatim, the transcripts were reviewed and coded using a process of inductive thematic analysis. We then used an iterative process to explore, review, reflect, and refine emergent codes and final themes. Ethical approval was not required based on the UK Health Research Authority decision tool. Results: Nine men, all with severe haemophilia B, aged 21 to 64 (median 34 years) participated. All were diagnosed as children; four had a previous family history and all described themselves as ‘well treated’ with self-managed home therapy and prophylaxis. None had received gene therapy. Parallels were observed in their goals. Thematic analysis classified them as achievable, unachievable and future goals. Achievable goals: Achieved despite living with haemophilia B, included education and employment, strong personal relationships, having a family, travelling, having a good social life and being able to participate in sports. Unachievable goals: Things that participants felt unable to achieve either now or in the future. These included changing attitudes of others, a recognition of lost opportunities including more physical, sporting and employment activities. Future goals: Those which might be achieved as treatments evolve. This included being more physically active, improved QoL for affected individuals and their families, greater ability to travel, and optimism for future treatments and their potential impact for future generations. The goals of PwHB often focused on personally meaningful everyday activities. Seemingly modest changes in individual circumstances could impact on QoL and wellbeing. QoL improvements were defined as equitable access to education and employment, increased confidence in undertaking physical activities, and greater ability to travel. Treatment innovations were identified as enhancing individualised patient preferences and reduced fear of bleeding along with its sequelae of pain and limited mobility. Conclusion: With improved access to novel therapeutic options, including gene therapy, PwHB are potentially able to experience equity to people without haemophilia in day-to-day life and activities. This will enable them to reimagine individual goals, their sense of what is ‘achievable’ and live their lives in personally meaningful ways.
- 4 December 2024
- Published by Wiley in Haemophilia
- Vol. 31 (1) , 5-6
Giving Choice a Voice: Commentary on Development of the World Federation of Hemophilia Shared Decision‐Making Tool
The shared decision‐making (SDM) tool developed by the World Federation of Hemophilia (WFH) provides a clear and concise overview of the process by which people with haemophilia (PwH) can collaborate with their healthcare professionals (HCPs) to engage and arrive at a therapeutic decision. This tool will be useful for all people with all bleeding disorders, not just PwH.
- 4 December 2024
- Published by Wiley in Haemophilia
- Vol. 31 (1) , 5-6
Giving Choice a Voice: Commentary on Development of the World Federation of Hemophilia Shared Decision‐Making Tool
The shared decision‐making (SDM) tool developed by the World Federation of Hemophilia (WFH) provides a clear and concise overview of the process by which people with haemophilia (PwH) can collaborate with their healthcare professionals (HCPs) to engage and arrive at a therapeutic decision. This tool will be useful for all people with all bleeding disorders, not just PwH.
- Open Access
- 15 November 2024
- Published by Wiley in Haemophilia
- Vol. 30 (6) , 1373-1382
One day at a time: Life with Glanzmann thrombasthenia – Qualitative results from the GT 360 study
Introduction: Glanzmann thrombasthenia (GT) is a platelet function disorder. Symptoms include bruising and bleeding, which may be severe and life‐threatening. The day‐to‐day experiences of those affected remain poorly documented.Aims: The Glanzmann's 360 study aimed to better understand the daily realities of living with GT, exploring psychological, social and medical challenges to identify unmet need.Methods: People with GT over 18 and caregivers of children with GT participated. Mixed methods research was used, including a survey and in‐depth interviews. The interviews, reported here, were audio‐recorded, transcribed and thematically analysed.Results: Nineteen interviews were conducted; 14 with people with GT and five caregivers. Mean age of those with GT was 32.9 years (range 2–78 years). Eight themes emerged: Diagnosis, Bleeding and Treatment, Menstruation, Fatigue, Identity, Abuse, Pregnancy, and The Future. Three participants described misdiagnosis. Caregivers reported early recognition and prompt diagnosis of their children. Bruising, the most commonly reported symptom, led to assumption of abuse. Six (32%) participants reported joint bleeds. External bleeding was normalised. Access to home treatment and local care were limited. Fatigue caused by anaemia was described. All women reported heavy menstrual bleeding. Choices around pregnancy were limited by ‘medical pessimism’. Nevertheless, participants remained hopeful for the development of improved treatment options.Conclusion: People with GT face significant and often overlooked challenges. There is need for improved medical and psychological treatment and support, increased awareness of these needs amongst healthcare professionals, and research into developing comprehensive care models that address medical and psychosocial needs of people with GT.
- 15 November 2024
- Published by Wiley in Haemophilia
- Vol. 30 (6) , 1373-1382
Open AccessOne day at a time: Life with Glanzmann thrombasthenia – Qualitative results from the GT 360 study
Introduction: Glanzmann thrombasthenia (GT) is a platelet function disorder. Symptoms include bruising and bleeding, which may be severe and life‐threatening. The day‐to‐day experiences of those affected remain poorly documented.Aims: The Glanzmann's 360 study aimed to better understand the daily realities of living with GT, exploring psychological, social and medical challenges to identify unmet need.Methods: People with GT over 18 and caregivers of children with GT participated. Mixed methods research was used, including a survey and in‐depth interviews. The interviews, reported here, were audio‐recorded, transcribed and thematically analysed.Results: Nineteen interviews were conducted; 14 with people with GT and five caregivers. Mean age of those with GT was 32.9 years (range 2–78 years). Eight themes emerged: Diagnosis, Bleeding and Treatment, Menstruation, Fatigue, Identity, Abuse, Pregnancy, and The Future. Three participants described misdiagnosis. Caregivers reported early recognition and prompt diagnosis of their children. Bruising, the most commonly reported symptom, led to assumption of abuse. Six (32%) participants reported joint bleeds. External bleeding was normalised. Access to home treatment and local care were limited. Fatigue caused by anaemia was described. All women reported heavy menstrual bleeding. Choices around pregnancy were limited by ‘medical pessimism’. Nevertheless, participants remained hopeful for the development of improved treatment options.Conclusion: People with GT face significant and often overlooked challenges. There is need for improved medical and psychological treatment and support, increased awareness of these needs amongst healthcare professionals, and research into developing comprehensive care models that address medical and psychosocial needs of people with GT.
- Open Access
- 22 October 2024
- Published by Wiley in Haemophilia
- Vol. 30 (6) , 1272-1280
A novel gene editing lexicon strategy for the haemophilia community: Research plan for development and preliminary results
Introduction: Despite the progress in gene editing platforms like CRISPR/Cas9 with the potential to transform the standard of care for haemophilia, the language used to explain and discuss gene editing is not aligned across the haemophilia community. Here, we present the objective and rationale for developing a clear, consistent, and globally aligned gene editing lexicon to address these communication gaps.Methods: Effectively communicating complex gene editing concepts requires a clear and consistent vocabulary. Through collaboration with a diversity of haemophilia stakeholders, our main goal is to develop an accurate, informative lexicon which avoids overpromising or highly technical terminology. Using an innovative process, representatives from several patient and scientific haemophilia organizations and select biotechnology companies will develop and refine language concepts to be tested with approximately seventy participants across the United States of America, United Kingdom, and Germany. Participants will include lived experience experts (LEEs) and haematologists. The process will be overseen by the Lexicon Steering Committee of global experts from leading scientific and patient organizations in the haemophilia and gene editing fields.Results: Initial feedback provided a robust foundation and rationale for building clear, consistent language around gene editing. This lexicon development framework will allow for increased understanding across the haemophilia community, including the development of valid informed consent and shared decision‐making materials.Conclusion: Results provide important building blocks for stimuli development and highlight the need for a novel gene editing lexicon. In the next phase, language stimuli will be tested with LEEs and haematologists to better understand audience preferences and help shape the final lexicon.
- 22 October 2024
- Published by Wiley in Haemophilia
- Vol. 30 (6) , 1272-1280
Open AccessA novel gene editing lexicon strategy for the haemophilia community: Research plan for development and preliminary results
Introduction: Despite the progress in gene editing platforms like CRISPR/Cas9 with the potential to transform the standard of care for haemophilia, the language used to explain and discuss gene editing is not aligned across the haemophilia community. Here, we present the objective and rationale for developing a clear, consistent, and globally aligned gene editing lexicon to address these communication gaps.Methods: Effectively communicating complex gene editing concepts requires a clear and consistent vocabulary. Through collaboration with a diversity of haemophilia stakeholders, our main goal is to develop an accurate, informative lexicon which avoids overpromising or highly technical terminology. Using an innovative process, representatives from several patient and scientific haemophilia organizations and select biotechnology companies will develop and refine language concepts to be tested with approximately seventy participants across the United States of America, United Kingdom, and Germany. Participants will include lived experience experts (LEEs) and haematologists. The process will be overseen by the Lexicon Steering Committee of global experts from leading scientific and patient organizations in the haemophilia and gene editing fields.Results: Initial feedback provided a robust foundation and rationale for building clear, consistent language around gene editing. This lexicon development framework will allow for increased understanding across the haemophilia community, including the development of valid informed consent and shared decision‐making materials.Conclusion: Results provide important building blocks for stimuli development and highlight the need for a novel gene editing lexicon. In the next phase, language stimuli will be tested with LEEs and haematologists to better understand audience preferences and help shape the final lexicon.
- Open Access
- 9 October 2024
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 8 (7) , 102586
Bleeding and quality of life in people with Glanzmann thrombasthenia—insights from the Glanzmann’s 360 study
- 9 October 2024
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 8 (7) , 102586
Open AccessBleeding and quality of life in people with Glanzmann thrombasthenia—insights from the Glanzmann’s 360 study